Diabetes and Hypertension Among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors

Overview

Journal ISRN AIDS

Specialty Infectious Diseases

Date 2013 Sep 21

PMID 24052880

Citations 28

Authors

Assane Diouf

Amandine Cournil

Khadidiatou Ba-Fall

Ndeye Fatou Ngom-Gueye

Sabrina Eymard-Duvernay

Ibrahima Ndiaye

Gilbert Batista

Papa Mandoumbe Gueye

Pape Samba Ba

Bernard Taverne

Eric Delaporte

Papa Salif Sow

Affiliations

Soon will be listed here.

Abstract

Cardiovascular risk factors in people on antiretroviral treatment (ART) are poorly documented in resource-constrained settings. A cross-sectional study was conducted in 2009 to assess prevalence of diabetes and hypertension in a sample of 242 HIV-infected patients who had initiated ART between 1998 and 2002 in Dakar, Senegal (ANRS 1215 observational cohort). World Health Organization (WHO) criteria were applied to diagnose diabetes and hypertension. Multiple logistic regressions were used to identify factors associated with diabetes and hypertension. Patients had a median age of 46 years and had received ART for a median duration of about 9 years. 14.5% had diabetes and 28.1% had hypertension. Long duration of ART (≥119 months), older age, higher body mass index (BMI), and higher levels of total cholesterol were associated with higher risks of diabetes. Older age, higher BMI at ART initiation, and higher levels of triglycerides were associated with higher risk of hypertension. This study shows that diabetes and hypertension were frequent in these Senegalese HIV patients on ART. It confirms the association between duration of ART and diabetes and highlights the need to implement programs for prevention of cardiovascular risk factors in HIV patients from resource-constrained settings.

Citing Articles

Hypertension among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis.

Chen A, Chan Y, Mocumbi A, Ojji D, Waite L, Beilby J Sci Rep. 2024; 14(1):16858.

PMID: 39039244 PMC: 11263367. DOI: 10.1038/s41598-024-67703-5.

Coprevalence and associations of diabetes mellitus and hypertension among people living with HIV/AIDS in Cameroon.

Ebasone P, Dzudie A, Peer N, Hoover D, Shi Q, Kim H AIDS Res Ther. 2024; 21(1):36.

PMID: 38824579 PMC: 11144319. DOI: 10.1186/s12981-024-00624-5.

HIV Infection and 90-Day Stroke Outcomes in Uganda: A Prospective Observational Cohort Study.

Mbonde A, Chang J, Musubire A, Okello S, Kayanja A, Moses A Neurol Clin Pract. 2024; 13(6):e200198.

PMID: 38495078 PMC: 10942001. DOI: 10.1212/CPJ.0000000000200198.

Prevalence and Factors Associated with Hypertension Among HIV Positive Patients on Antiretroviral Therapy: A Hospital-Based Cross-Sectional Study in Rwanda.

Uwanyirigira D, Biracyaza E, Uzabakiriho I, Omolo J, Hakizayezu F, Nzayirambaho M Vasc Health Risk Manag. 2024; 19:857-870.

PMID: 38162226 PMC: 10757801. DOI: 10.2147/VHRM.S442108.

Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study.

Jumare J, Dakum P, Sam-Agudu N, Memiah P, Nowak R, Bada F BMC Endocr Disord. 2023; 23(1):160.

PMID: 37507703 PMC: 10375691. DOI: 10.1186/s12902-023-01419-x.

References

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

Tien P, Schneider M, Cole S, Levine A, Cohen M, DeHovitz J . Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007; 21(13):1739-45. DOI: 10.1097/QAD.0b013e32827038d0. View

Bergersen B, Sandvik L, Dunlop O, Birkeland K, Bruun J . Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003; 22(12):731-6. DOI: 10.1007/s10096-003-1034-z. View

De Wit S, Sabin C, Weber R, Worm S, Reiss P, Cazanave C . Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008; 31(6):1224-9. PMC: 2746200. DOI: 10.2337/dc07-2013. View

Zannou D, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J . Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009; 14(3):371-80. DOI: 10.1177/135965350901400307. View

Deeks S, Phillips A . HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009; 338:a3172. DOI: 10.1136/bmj.a3172. View

. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635):293-9. PMC: 3130543. DOI: 10.1016/S0140-6736(08)61113-7. View

Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna G, Brun S . Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008; 105(10):3879-84. PMC: 2268833. DOI: 10.1073/pnas.0800050105. View

Howard A, Floris-Moore M, Arnsten J, Santoro N, Fleischer N, Lo Y . Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005; 40(10):1492-9. PMC: 2104646. DOI: 10.1086/429824. View

10.

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

11.

Crane H, Grunfeld C, Harrington R, Kitahata M . Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 2009; 10(8):496-503. PMC: 2729358. DOI: 10.1111/j.1468-1293.2009.00720.x. View

12.

Cahn P, Leite O, Rosales A, Cabello R, Alvarez C, Seas C . Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis. 2010; 14(2):158-66. DOI: 10.1590/s1413-86702010000200008. View

13.

Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud J, Perronne C . Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002; 34(10):1396-405. DOI: 10.1086/339866. View

14.

Cattelan A, Trevenzoli M, Naso A, Meneghetti F, Cadrobbi P . Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis. 2000; 30(3):619-21. DOI: 10.1086/313728. View

15.

Thiebaut R, El-Sadr W, Friis-Moller N, Rickenbach M, Reiss P, Monforte A . Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005; 10(7):811-23. DOI: 10.1177/135965350501000706. View

16.

Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D . Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008; 48(5):590-8. DOI: 10.1097/QAI.0b013e31817efb54. View

17.

Silva E, Bassichetto K, Lewi D . Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol. 2009; 93(2):113-8. DOI: 10.1590/s0066-782x2009000800008. View

18.

de Arruda Junior E, Lacerda H, Moura L, de Albuquerque M, de Barros Miranda Filho D, Diniz G . Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis. 2010; 14(3):281-7. DOI: 10.1590/s1413-86702010000300014. View

19.

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B . Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007; 45(1):111-9. DOI: 10.1086/518619. View

20.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View